United States Cancer Biomarkers Market Size (2024 - 2029)

The United States cancer biomarkers market is experiencing growth driven by the increasing incidence of cancer and the higher acceptance of cancer treatments. The expanding use of biomarkers in drug development is creating significant opportunities for market participants. Key players are concentrating on research and development to introduce new and reliable biomarkers aimed at enhancing diagnosis and therapy. The rising number of cancer cases and the emphasis on innovative drug development are pivotal in propelling the overall market size.

Home Market Analysis Healthcare Research Medical Devices Research Medical Supplies Research Medical Consumables Research Laboratory Supplies Research United States Cancer Biomarkers Market Market Size

Market Size of United States Cancer Biomarkers Industry

United States Cancer Biomarkers Market Size
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 11.20 %

Major Players

United States Cancer Biomarkers Market Key Players

*Disclaimer: Major Players sorted in no particular order

US Cancer Biomarkers Market Analysis

The major factors that are driving the market growth include the increasing incidence of cancer, globally, and higher acceptance of treatments for cancer in the country and increasing usage of biomarkers in drug development. The rising number of cancer cases is creating tremendous opportunities for market players. The major market players are focusing on R&D activities, to bring new and reliable biomarkers for improving the diagnosis and therapy. The National Cancer Institute (NCI) has stated that the national spending on cancer care is expected to reach USD 156 billion by 2020.

According to the estimates of the American Cancer Society, in 2018, there were 1,735,350 new cancer cases diagnosed and 609,640 deaths due to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer. Therefore the increasing cancer cases and the rising focus on Innovative drug development helps in driving the overall market growth.

US Cancer Biomarkers Industry Segmentation

As per the scope of the report, biomarkers are chemical, physical, or biological parameters, which can be used to indicate the disease states. Oncology biomarkers offer high-speed, non-invasive cancer diagnoses, and enhance cancer detection and screening. The cancer biomarkers market is segmented by disease, type, profiling technology.

By Disease
Prostate Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Others
By Type
Protein Biomarkers
Genetic Biomarkers
Other Types
By Profiling Technology
OMICS Technology
Imaging Technology
Immunoassays
Cytogenetics
Need A Different Region Or Segment?
Customize Now

United States Cancer Biomarkers Market Size Summary

The United States cancer biomarkers market is experiencing significant growth, driven by the increasing incidence of cancer and the higher acceptance of cancer treatments. The rising number of cancer cases presents substantial opportunities for market players, who are heavily investing in research and development to discover new and reliable biomarkers that can enhance diagnosis and therapy. The focus on innovative drug development is further propelling market expansion, as evidenced by the substantial national spending on cancer care. Common cancers in the United States, such as breast, lung, prostate, colorectum, bladder, and skin cancer, are contributing to the market's growth trajectory.

The market is characterized by intense competition, with major players like Abbott Laboratories Inc., Agilent Technologies, Biomerieux, F. Hoffmann-La Roche Ltd, Hologic Inc., Illumina Inc., and Thermo Fisher Scientific holding significant market shares. The increasing burden of lung cancer, influenced by lifestyle changes and air pollution, is particularly noteworthy, as it drives demand for effective biomarkers and treatments. Despite the challenges posed by cancer, advancements in biomarker technology and drug development are expected to sustain the market's robust growth in the coming years.

Explore More

United States Cancer Biomarkers Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increased Burden of Cancer in the US

      2. 1.2.2 Increasing Focus on Innovative Drug Development

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Diagnosis and Reimbursement Issues

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Disease

      1. 2.1.1 Prostate Cancer

      2. 2.1.2 Breast Cancer

      3. 2.1.3 Lung Cancer

      4. 2.1.4 Colorectal Cancer

      5. 2.1.5 Others

    2. 2.2 By Type

      1. 2.2.1 Protein Biomarkers

      2. 2.2.2 Genetic Biomarkers

      3. 2.2.3 Other Types

    3. 2.3 By Profiling Technology

      1. 2.3.1 OMICS Technology

      2. 2.3.2 Imaging Technology

      3. 2.3.3 Immunoassays

      4. 2.3.4 Cytogenetics

United States Cancer Biomarkers Market Size FAQs

The United States Cancer Biomarkers Market is projected to register a CAGR of 11.20% during the forecast period (2024-2029)

Abbott Laboratories Inc., Thermo Fisher Scientific, Biomerieux, Illumina Inc. and F. Hoffmann-La Roche Ltd are the major companies operating in the United States Cancer Biomarkers Market.

United States Cancer Biomarkers Report Snapshots

United States Cancer Biomarkers Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)